(Albany, United States) As per DelveInsight’s assessment, globally, the Atherosclerosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Atherosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Atherosclerosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Atherosclerosis clinical trials studies, Atherosclerosis NDA approvals (if any), and product development activities comprising the technology, Atherosclerosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Atherosclerosis pipeline treatment landscape of the report, click here @ Atherosclerosis Pipeline Outlook

 

Key Takeaways from the Atherosclerosis Pipeline Report

• DelveInsight’s Atherosclerosis Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline treatment therapies.
• The leading Atherosclerosis Companies working in the market include Regeneron/Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra, Millennium Pharmaceuticals, Daiichi Sankyo, Band Therapeutic, Innomedica, Chugai Pharmaceutical, Repair Biotechnologies, Northstar medical radioisotopes, Entos therapeutics, Caladrius Biosciences, Novo Nordisk, Esperion Therapeutics, Immusoft Corp, Kaleido Biosciences, Takeda Pharmaceutical, MetrioPharm, and others.
• Promising Atherosclerosis Pipeline Therapies in the market include Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid, MLDL1278A, rilapladib, 18F Fluorodeoxylucose (FDG)-PET, Glipizide, Rosiglitazone Maleate, Pactimibe, Olmesartan medoxomil, Divaza, and others
• On June 2023, Daiichi Sankyo Inc announced a study of phase 3 clinical trials for Olmesartan medoxomil.The purpose of this study is to determine the efficacy of treatment with olmesartan medoxomil, an Angiotensin Receptor Blocker, compared to placebo on the blood levels of surrogate markers of vascular inflammation for atherosclerotic disease. Patients will be randomized to receive either olmesartan medoxomil or placebo for one year.
• On June 2023, Amgen announced a study of clinical trials for Lp(a) Screening.The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold.
• On January 2023, Yinyi (Liaoning) Biotech Co., Ltd announced a study of clinical trials for Drug eluting balloon (Vmoky). A prospective, multi-center, single-arm study to evaluate the safety and efficacy of drug eluting balloon catheter for the treatment of patients with symptomatic intracranial atherosclerotic stenosis.

 

Atherosclerosis Overview

Plaque (fatty deposits) build up in arteries is called atherosclerosis. These deposits are made up of cholesterol, fatty substances, cellular waste products, calcium and fibrin (a clotting material in the blood). As plaque builds up, the wall of the blood vessel thickens.

 

To explore more information on the latest breakthroughs in the Atherosclerosis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

 

Atherosclerosis Emerging Drugs Profile

• Aloricumab: Sanofi/ Regeneron
• VB 201: VBL therapeutics

 

Atherosclerosis Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Atherosclerosis. The companies which have their Atherosclerosis drug candidates in the most advanced stage, i.e. Registration include, Sanofi/ Regeneron.

 

Request a sample and discover the recent advances in Atherosclerosis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

 

Atherosclerosis Drugs and Companies

• Rivaroxaban (BAY59-7939, Xarelto): Bayer
• Acetylsalicylic acid: Janssen
• MLDL1278A: Genentech
• Rilapladib: GlaxoSmithKline

 

Atherosclerosis Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Atherosclerosis Therapeutics Market include-

Regeneron/Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra, Millennium Pharmaceuticals, Daiichi Sankyo, Band Therapeutic, Innomedica, Chugai Pharmaceutical, Repair Biotechnologies, Northstar medical radioisotopes, Entos therapeutics, Caladrius Biosciences, Novo Nordisk, Esperion Therapeutics, Immusoft Corp, Kaleido Biosciences, Takeda Pharmaceutical, MetrioPharm, and others.

 

Dive deep into rich insights for drugs for Atherosclerosis Pipeline, click here for Atherosclerosis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

 

Scope of the Atherosclerosis Pipeline Report

• Coverage- Global
• Atherosclerosis Companies- Regeneron/Sanofi, Immunitor, Novartis, MedImmune, Cerenis Therapeutics, AFFiRiS, VBL Therapeutics, Abcentra, Millennium Pharmaceuticals, Daiichi Sankyo, Band Therapeutic, Innomedica, Chugai Pharmaceutical, Repair Biotechnologies, Northstar medical radioisotopes, Entos therapeutics, Caladrius Biosciences, Novo Nordisk, Esperion Therapeutics, Immusoft Corp, Kaleido Biosciences, Takeda Pharmaceutical, MetrioPharm, and others.
• Atherosclerosis Pipeline Therapies- Rivaroxaban (BAY59-7939, Xarelto), Acetylsalicylic acid, MLDL1278A, rilapladib, 18F Fluorodeoxylucose (FDG)-PET, Glipizide, Rosiglitazone Maleate, Pactimibe, Olmesartan medoxomil, Divaza, and others
• Atherosclerosis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Atherosclerosis Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Atherosclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atherosclerosis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Atherosclerosis Collaboration Deals
9. Late Stage Products (Regsitered)
10. Aloricumab: Sanofi/ Regeneron
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VB 201: VBL therapeutics
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. BT 200: Band Therapeutics
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Atherosclerosis Key Companies
20. Atherosclerosis Key Products
21. Atherosclerosis- Unmet Needs
22. Atherosclerosis- Market Drivers and Barriers
23. Atherosclerosis- Future Perspectives and Conclusion
24. Atherosclerosis Analyst Views
25. Atherosclerosis Key Companies
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services